Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use OCREVUS ZUNOVO safely and effectively. See full prescribing information for OCREVUS ZUNOVO. OCREVUS ZUNOVO® (ocrelizumab and hyaluronidase-ocsq) injection, for subcutaneous use Initial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
OCREVUS ZUNOVO is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults
- generic_name
- ocrelizumab and hyaluronidase
- product_names
- ocrelizumab and hyaluronidase
- ndc
- 50242-554, 50242-554-01, 50242-554-86
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en